#PetVivo #Announces #Financial #Results #Quarter #Fiscal #Year
The conference call begins today at 4:00 p.m. Central Time
EDINA, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (“PetVivo” or the “Company”) (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, reports financial results for the second quarter of fiscal 2023 known The company began commercializing its lead product Spryng™ with OsteoCushion™ Technology, a vet-administered intra-articular injection for the treatment of lameness and other joint conditions such as osteoarthritis in dogs and horses, in September 2021.
Highlights from the second quarter of fiscal 2023 and recent weeks include the following (all comparisons are to second quarter of fiscal 2022 unless otherwise noted):
- Revenue of $223,280 for the three months ended September 30, 2022 compared to revenue of $4,977 for the three months ended…
Read on GNW: PetVivo Announces Financial Results for the Second Quarter of Fiscal Year 2023
